

REVIEW

Glycine receptor mouse mutants: model systems for human hyperekplexia

Natascha Schaefer¹, Georg Langlhofer¹, Christoph J Kluck² and Carmen Villmann¹

¹Institute for Clinical Neurobiology, Julius-Maximilians-University of Würzburg, Würzburg, Germany, and ²Institute of Biochemistry, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

Correspondence

Carmen Villmann, Institute for Clinical Neurobiology, University of Würzburg, Versbacherstr. 5, Würzburg D-97078, Germany.
E-mail: villmann_c@ukw.de

Keywords

glycine receptor; mouse models; spontaneous; knock-in; domain complementation

Received

3 January 2013

Revised

19 July 2013

Accepted

2 August 2013

Human hyperekplexia is a neuromotor disorder caused by disturbances in inhibitory glycine-mediated neurotransmission. Mutations in genes encoding for glycine receptor subunits or associated proteins, such as *GLRA1*, *GLRB*, *GPHN* and *ARHGEF9*, have been detected in patients suffering from hyperekplexia. Classical symptoms are exaggerated startle attacks upon unexpected acoustic or tactile stimuli, massive tremor, loss of postural control during startle and apnoea. Usually patients are treated with clonazepam, this helps to dampen the severe symptoms most probably by up-regulating GABAergic responses. However, the mechanism is not completely understood. Similar neuromotor phenotypes have been observed in mouse models that carry glycine receptor mutations. These mouse models serve as excellent tools for analysing the underlying pathomechanisms. Yet, studies in mutant mice looking for postsynaptic compensation of glycinergic dysfunction via an up-regulation in GABA_A receptor numbers have failed, as expression levels were similar to those in wild-type mice. However, presynaptic adaptation mechanisms with an unusual switch from mixed GABA/glycinergic to GABAergic presynaptic terminals have been observed. Whether this presynaptic adaptation explains the improvement in symptoms or other compensation mechanisms exist is still under investigation. With the help of spontaneous glycine receptor mouse mutants, knock-in and knock-out studies, it is possible to associate behavioural changes with pharmacological differences in glycinergic inhibition. This review focuses on the structural and functional characteristics of the various mouse models used to elucidate the underlying signal transduction pathways and adaptation processes and describes a novel route that uses gene-therapeutic modulation of mutated receptors to overcome loss of function mutations.

Abbreviations

CLR, cys-loop receptor; ECD, extracellular domain; GEFS+, generalized epilepsy with febrile seizures plus; Gly, glycine; M1–M4, transmembrane domains 1–4; PTX, picrotoxin

History of human hyperekplexia

The ability of strychnine to influence inhibitory reflexes and to convert these into excitatory reflexes was originally shown by Owen and Sherrington (1911). Hyperekplexia (*Startle disease*, *Stiff baby syndrome*, *STHE* – *startle disease* or *hyperekplexia*, OMIM 149400) was first described by Kirstein and Silfverskiöld (1958) long before recombinant systems became available. In 1966 Suhren *et al.* reported a family with 25 members through five generations that suffered from abnormal severe startle reactions. This family was clinically described as having an autosomal dominant inheritance with an abnormal startle reaction in affected

patients, which was elicited by different stimuli that did not provoking similar reactions in healthy controls. With the help of electroencephalographic (EEG) observations, a sub-cortical origin, for example, some midline structure like the brainstem, was proposed as being the source for this abnormal startle reaction. Furthermore, the patients were conscious during the attacks and the observed EEG waves did not correspond to those of epileptic patients (Suhren *et al.*, 1966). These patients were treated with clonazepam, a benzodiazepine and potent 5-HT agonist. It was also reported that alcohol, phenobarbital and chlorthalidone were able to decrease the intensity of the symptoms (Andermann *et al.*, 1980).

Later on, two other case reports of families with hyperekplexia were reported by Morley *et al.* (1982) and Kurczynski (1983), and in 1991, two Japanese families with several affected individuals were described with an autosomal dominant inheritance and abnormal startle responses. Recessive forms of inheritance were also depicted from other three families (Hayashi *et al.*, 1991). Only one year later, the genetic locus of hyperekplexia was deduced, with the help of linkage analysis and radiation hybrid mapping, as being on the long arm of chromosome 5. Two possible candidate genes, *GABRA1* and *GABRG2*, encoding GABA receptor subunits and three other loci, *RPS14*, *SPARC* and *GLRA1*, were determined as the source of the abnormal startle responses (Ryan *et al.*, 1992a; 1992b). Finally, Shiang *et al.* identified the *GLRA1* gene as the candidate gene for sequence alterations in affected patients because of the following reasons: (i) *GLRA1* was mapped on the long arm of chromosome 5 near *SPARC* (osteonectin) and *RPS14* (ribosomal protein S14), both of which were marked in the hyperekplexia region via radiation hybrid mapping; (ii) a detailed analysis showed that *GLRA1* was directly in the middle of the candidate region; and (iii) *GLRA1* encodes for a subunit of the inhibitory glycine receptor and can be antagonized by strychnine, which in sub-lethal doses causes hypertonia and exaggerated startle responses in mice. This phenomenon was similar to symptoms described in human patients suffering from hyperekplexia. Shiang *et al.* (1993) identified two mutations in four affected individuals from four different families with a nucleotide exchange G1192T/A. No mutation was found in 50 unaffected individuals. These single nucleotide exchanges resulted in an amino acid exchange from arginine at position 271 to leucine or glutamine (Figure 1). Meanwhile, several additional mutations have been identified, for example, Y279C (Shiang *et al.*, 1995), Q266H (Milani *et al.*, 1996), K276E (Seri *et al.*, 1997), P250T (Saul *et al.*, 1999), V260M (del Giudice *et al.*, 2001), S267N (Becker *et al.*, 2008) and Y128C (Chung *et al.*, 2010) (Figure 1; Table 1).

Glycine receptor structure and determinants

Overall architecture

The anion-conductive glycine (Gly) receptor is a pentameric ligand-gated ion channel that mediates fast synaptic inhibition in mammalian spinal cord and brain stem. The Gly receptor was purified via an affinity chromatography column using amino strychnine agarose as a resin and later several subunits were cloned (Pfeiffer *et al.*, 1982; Grenningloh *et al.*, 1990). Gly receptors belong to the superfamily of Cys-loop (CL) receptors, which also comprise GABA_A, type A and C (GABA_A), nicotinic ACh (nACh) and 5-hydroxytryptamine (type 3, 5-HT₃) receptors (Karlin and Akabas, 1995; for receptor nomenclature see Alexander *et al.*, 2011). All members of this family share a common topological organization of different subunits in a pentameric conformation. Each of them consists of a large amino-terminal extracellular domain (ECD) that harbours the ligand-binding sites followed by four α -helical transmembrane domains (M1–M4) connected by intracellular and extracellular loop structures.

The C-terminus is short and extracellularly localized (Lynch, 2004; Hilf and Dutzler, 2008).

The ECD is determined by 10 β -strands that are organized in two sheets to form a β -sandwich and a short α -helix. The loop between the sixth and seventh β -strand is constrained by a disulphide bond between two highly conserved cysteine residues, responsible for the name of the superfamily. The order of β -strands is similar to a modified Ig topology (Bork *et al.*, 1994). The M2 is followed by a large intracellular loop between M3 and M4. Gly receptors assemble from five subunits with each contributing one amphipathic M2 domain to the central ion channel pore localized 50 Å below the ligand-binding site (Unwin, 1995; Brejc *et al.*, 2001; Miller and Smart, 2010). The subunits are arranged like staves of a barrel around a symmetry axis that defines the ion permeation pathway.

The configuration of the native Gly receptor is still debatable. Independent approaches, such as the initial Gly receptor characterization of purified receptor protein, studies on concatameric receptors and the determination of subunit arrangements using atomic force microscopy of tagged α and β subunits, have revealed a heteromeric stoichiometry of 2 α (48 kDa) and 3 β subunits (58 kDa) (Pfeiffer *et al.*, 1982; Grudzinska *et al.*, 2005; Yang *et al.*, 2012). Recently, a heteromeric configuration of 3 α :2 β was determined using single-molecule imaging and stepwise photobleaching of venus fluorescent protein-tagged Gly receptor α and β subunits expressed in *Xenopus* oocytes (Durisic *et al.*, 2012). With regard to the existence of an α - α or β - β interface within the pentameric receptor complexes, the correct assignment of the ion channel subunit composition is important for developing specific therapeutic substances.

The ECDs form the agonist binding sites at subunit interfaces, which are determined by loops A, B and C from the principal (+) interface and loops D, E and F from the complementary (–) subunit. The interface between the ECD and the transmembrane domains is termed the transition zone. Following ligand binding, this receptor domain enables conformational changes that are required to allow ion channel opening. This zone comprises domains of the ECD, for example, loop 2, the Cys-loop, the pre-M1 linker and the M2–M3 loop (Brejc *et al.*, 2001; Unwin, 2005; Hibbs and Gouaux, 2011). A re-arrangement of the transition zone leads, in turn, to a reconfiguration of the M2–M3 loop. Rotation or tilting of the M2 helix during conformational changes ultimately produces channel opening (Pless *et al.*, 2007; Lee *et al.*, 2009).

The ECD

Considerable progress in the definition of amino acid residues involved in ligand binding has been made following the determination of the X-ray structure of the ACh-binding protein (AChBP). AChBP is a molluscan homologue of the ECD of nACh receptors. Meanwhile, the structures of two prokaryotic homologues ELIC and GLIC and the invertebrate glutamate-gated chloride channel (GluCl) from *Caenorhabditis elegans* have been resolved (Brejc *et al.*, 2001; Hilf and Dutzler, 2008; 2009; Hibbs and Gouaux, 2011). GLIC and ELIC presumably represent the closed and open state of CL receptors respectively (Bocquet *et al.*, 2009). Most conserved ECD residues are hydrophobic, resulting in two hydrophobic




Figure 1

Homology models of the human (A, blue – α subunit, green – β subunit) and mouse (B, grey – α subunit, yellow – β subunit) Gly receptor subunits based on the crystal structure of the *Caenorhabditis elegans* glutamate-gated chloride channel (GluCl) solved by Hibbs and Gouaux (2011) showing the mutated amino acid positions affected in hyperekplexia. Two neighbouring subunits of a pentamer are shown. Amino acid exchanges due to recessive mutations, compound heterozygous mutations or deletions with frameshifts resulting in premature stop codons as well as those with no known mode of inheritance are shown as magenta sticks, while amino acid exchanges based on dominant mutations are depicted in orange. (B) Murine knock-in mutations are shown in italics. Note that in the homology models the large intracellular loop domain (ICD) between M helices 3 and 4 was left out as the crystallized GluCl variant also just had a minimal ICD of three amino acids. Therefore, Gly receptor variants having changes in the ICD region are listed, but not represented in the structures modelled.

pockets at the subunit interfaces (Brejc *et al.*, 2001). Several lines of evidence exist that these interfaces do indeed represent the ligand-binding sites (Corringer *et al.*, 2000). The binding pockets are rich in aromatic residues, which undergo cation– π interactions with the amine nitrogen of the agonist. These connections substantially contribute to agonist

binding (Zhong *et al.*, 1998). The most common location for such an interaction is an aromatic residue on loop B (Trp¹⁴⁹ of the nACh receptor, Trp¹⁸³ of the 5-HT₃ receptor, Tyr¹⁹⁸ of the GABA_c receptor and Phe¹⁵⁹ of the Gly receptor) (Pless *et al.*, 2008). The functional role of the Gly receptor ECD was further demonstrated by a pronounced effect on single

Table 1Mutations in the human *GLRA1* gene

Mutation	Mode of inheritance	Effect	References
Deletion Exon 1–6 Deletion 1–7	Autosomal recessive	n.d.	Becker <i>et al.</i> (2006); Brune <i>et al.</i> (1996)
R65L/ R65W	Autosomal recessive	Non-functional	Chung <i>et al.</i> (2010)
W68C	Autosomal recessive	n.d.	Tsai <i>et al.</i> (2004)
R72H	Autosomal recessive	n.d.	Coto <i>et al.</i> (2005)
E103K	Autosomal recessive	Reduced maximal currents	Chung <i>et al.</i> (2010)
Y128C	Autosomal dominant	Reduced maximal currents	Chung <i>et al.</i> (2010)
M147V	Autosomal recessive	n.d.	Rees <i>et al.</i> (2001)
D165G	Autosomal recessive	Reduced maximal currents	Chung <i>et al.</i> (2010)
W170S	Autosomal recessive	n.d.	Al-Futaisi <i>et al.</i> (2012)
Y197X	Autosomal recessive	n.d.	Chung <i>et al.</i> (2010)
Y202X	Autosomal recessive	Reduced cell surface expression	Rees <i>et al.</i> (2001)
R218Q	Autosomal recessive	Reduced cell surface expression	Castaldo <i>et al.</i> (2004); Miraglia <i>et al.</i> (2003)
Y228C	Autosomal recessive	n.d.	Forsyth <i>et al.</i> (2007)
S231R/ S231N	Autosomal recessive	Reduced cell surface expression	Humeny <i>et al.</i> (2002); Villmann <i>et al.</i> (2009b); Chung <i>et al.</i> (2010)
W239C	Autosomal recessive	n.d.	Gilbert <i>et al.</i> (2004)
I244N A ⁻¹	Autosomal recessive	Reduced glycine affinity, reduced maximal currents, increased desensitization	Rees <i>et al.</i> (1994); Lynch <i>et al.</i> (1997); Villmann <i>et al.</i> (2009b)
P250T	Autosomal dominant	Reduced single channel conductance, reduced glycine sensitivity	Saul <i>et al.</i> (1999)
R252H/R252C/R392H	Compound heterozygous, autosomal recessive	Reduced cell surface expression	Vergouwe <i>et al.</i> (1999); Rea <i>et al.</i> (2002); Villmann <i>et al.</i> (2009b); Chung <i>et al.</i> (2010)
G254D	Autosomal recessive	Non-functional	Chung <i>et al.</i> (2010)
V260M	Autosomal dominant	Changes in taurine binding	del Giudice <i>et al.</i> (2001); Castaldo <i>et al.</i> (2004)
T265I	Autosomal dominant	Co-transfection with β subunit required for functionality	Chung <i>et al.</i> (2010)
Q266H	Autosomal dominant	Reduced open probability, reduced glycine sensitivity	Milani <i>et al.</i> (1996); Moorhouse <i>et al.</i> (1999)
S267N	Autosomal dominant	Reduced glycine sensitivity	Becker <i>et al.</i> (2008); Findlay <i>et al.</i> (2005)
S270T	Autosomal dominant	n.d.	Lapunzina <i>et al.</i> (2003)
R271Q/L/P/X	Autosomal dominant	Reduced glycine sensitivity, reduced single channel conductance	Ryan <i>et al.</i> (1992b); Shiang <i>et al.</i> (1993); Langosch <i>et al.</i> (1994); Rajendra <i>et al.</i> (1994)
K276E/Q	Autosomal dominant	Reduced glycine sensitivity, reduced open probability	Elmslie <i>et al.</i> (1996); Lewis <i>et al.</i> (1998); Lynch <i>et al.</i> (1997)
Y279C/S/X	Autosomal dominant	Reduced glycine sensitivity, reduced maximal current responses	Filatov and White (1995); Lape <i>et al.</i> (2012); Lynch <i>et al.</i> (1997)
S296X	Autosomal recessive	n.d.	Bellini <i>et al.</i> (2007)
R316X	Autosomal recessive	n.d.	Tsai <i>et al.</i> (2004)
G342S	Compound heterozygous	n.d.	Rees <i>et al.</i> (2001)
R392H/R252H/R252C	Compound heterozygous, autosomal recessive	Reduced cell surface expression	Vergouwe <i>et al.</i> (1999); Rea <i>et al.</i> (2002); Villmann <i>et al.</i> (2009b); Chung <i>et al.</i> (2010)

n.d., not determined.

channel conductances when adjacent charged residues localized in β -strands $\beta 2$ (D57 and R59) and $\beta 4$ (K104, G105) were mutated into homologous residues of the nACh $\alpha 1$ receptors. These data revealed that the ECD determines the ion selectivity and permeation of Cys-loop receptors (Brams *et al.*, 2011a). Moreover, the highly conserved amino acid D97 on loop A was shown to construct an inter-subunit electrostatic bond, the disruption of which resembles a critical step in channel activation (Todorovic *et al.*, 2010). Previous studies have identified three residues within the ECD of Gly receptors including D97 that cause a spontaneous opening of the channel: D97R, F99A and Y128C (Beckstead *et al.*, 2002; Miller *et al.*, 2008; Chung *et al.*, 2010). Structural modelling of the Gly $\alpha 1$ receptor mutant Y128C predicted an induction of a short α -helix in the ECD directly overlying the M regions, suggesting a common mechanism of tonic channel opening (Chung *et al.*, 2010).

In addition to the eponymous Cys-loop, the ECD of the Gly receptor carries two additional cysteine residues in loop C that are conserved in the recently solved GluCl receptor structure. These cysteines have been found to form another disulphide bond, which affects both the formation of the eponymous Cys-loop and the correct membrane integration needed for channel function (Vogel *et al.*, 2009; Hibbs and Gouaux, 2011). Several lines of evidence indicate a rigid body capping motion of loop C upon agonist binding, thereby trapping bound agonist molecules (Hansen *et al.*, 2005). At the complementary subunit interfaces, voltage-clamp fluorometry and site-directed mutagenesis analysis identified several residues on Gly receptor loops D, E to be crucial for ligand recognition and discrimination (Grudzinska *et al.*, 2005; Pless and Lynch, 2009). Apart from distinct loop structures, the pre-M1 linker at the interface between ECD and M1 of Gly receptors was demonstrated to be part of the transition zone translating ligand binding into channel opening (Lee *et al.*, 2009). It has been reported that electrostatic repulsion between a pair of residues that are in close proximity to each other in the tertiary structure, but are discrete from the pre-M1 and Cys-loop subdomains, respectively, prevents surface expression of Gly receptors (Shan and Lynch, 2012). These results emphasize the importance of an intact transition zone for both proper receptor assembly and transmission of agonist-induced conformational changes to the channel gate.

The ion channel pore

Most missense mutations located either in or near the M2 pore-lining domain affect ion channel properties (Harvey *et al.*, 2008). Structural analysis showed the M2 to be kinked radially inwards, attaining a minimum pore diameter at approximately its midpoint (Miyazawa *et al.*, 2003). Ion selectivity is controlled by sets of charged residues near the mouth of the channel (Hucho and Weise, 2001). The following Gly $\alpha 1$ receptor subunit residues are localized in the ion pore: G2', T6', R19' and A20' (Saitoh *et al.*, 1994; Shan *et al.*, 2001b). Other residues that most likely face the pore have been predicted by homology with other CL receptors: T7', L9', T10', T13', S16' and G17' (Akabas *et al.*, 1994; Xu and Akabas, 1996; Lynch, 2004). The M2 numbering system assigns position 1' to the putative cytoplasmic end of M2 and 19' to the outermost residue. When viewed from a α -helical

net, these residues form a hydrophilic 'strip' along one site of an otherwise hydrophobic α -helix. The 9' leucine ring is conserved throughout the CL receptor family, and substitution with hydrophilic residues in nACh, GABA $_A$ and Gly receptors has been shown to increase the tendency of the channel to open in response to agonist. Therefore, hydrophobicity of this ring stabilizes the closed state of the channel (Kwok *et al.*, 2001). Although other regions contribute to the modulation of conductance and selectivity of CL receptors, the minimal determinants of selectivity are the -1'Ala and -2'Pro positions for anions and the -1'Glu for cations, with no requirement for positively charged amino acids in the pore of anion-selective channels (Keramidas *et al.*, 2004; Sunesen *et al.*, 2006; Thompson *et al.*, 2010). For the Gly receptor, the mutations P250 Δ (-2P'), A251E and T265V have been performed, which resulted in cation selectivity (Keramidas *et al.*, 2004). The critical effect of P250 was further demonstrated in a mutagenesis study, where isotropic forces, charge and hydrophobicity were identified as critical determinants of receptor function (Breitinger *et al.*, 2001) (Figure 2). Thus, P250 may serve a dual role (i) positioning neighbouring residues and (ii) representing a critical residue at the protein surface near the inner mouth of the ion channel. Apart from M2's function as an ion channel pore, it has been suggested that the main binding sites for allosteric modulation are located within the M-domain (Mihic *et al.*, 1997; Nury *et al.*, 2010; James *et al.*, 2013). These studies highlight the role of two cavities in the allosteric modulation processes, both are located in the upper part of the M-domains – one at the centre of the four helices bundle in each subunit and one at the interface between subunits (Duret *et al.*, 2011).

Pharmacology of glycine receptors

Low-efficacy agonists

Apart from the major agonist glycine, the β -amino acids taurine and β -alanine have been proposed as endogenous lower efficacy Gly receptor agonists (Laube *et al.*, 2002). At low concentrations, they competitively inhibit glycine responses, whereas high concentrations elicit significant membrane currents, albeit their affinities and efficacies are lower than that of glycine (Schmieden and Betz, 1995; Breitinger and Becker, 1998).

Zinc

Opposite concentration-dependent effects apply to Zn $^{2+}$ -mediated modulation of Gly receptors. Low concentrations of Zn $^{2+}$ (<10 μ M) enhance glycine-mediated currents by increasing the agonist affinity without changing the maximal inducible current. Higher concentrations lead to an inhibitory effect (Laube *et al.*, 1995a; Lynch *et al.*, 1998). Both the potentiation and inhibition of Gly receptor currents by Zn $^{2+}$ are reversible. It has been suggested that Zn $^{2+}$ affects agonist association as well as the efficacy of channel opening (Laube *et al.*, 2000).

Antagonists

Strychnine and d-tubocurarine (d-TC) are alkaloids from poisonous plants that act as competitive antagonists with very




Figure 2

Dominant hyperekplexia mutants result in changes in pharmacological properties of the Gly receptor $\alpha 1$ channel (modified from Breiting *et al.*, 2001). (A) The human mutation P250T (Thr) was introduced into the Gly receptor $\alpha 1$ cDNA and transfected into HEK293 cells. Following application of glycine (1 mM), mutant channels desensitize much faster than those of wild-type (wt Pro) controls (non-desensitizing wt compared to 121 ± 6 ms for P250T). (B) EC_{50} curves for glycine were measured using various glycine concentrations from 5 μ M to 10 mM. With P250T, the glycine dose–response curve shows a rightward shift to lower glycine affinities (arrow, reduced by 24-fold compared with wild-type control).

high affinity for Gly and nACh receptors. In contrast to high affinity, both have low specificity as d-TC also antagonizes the effect of 5-HT on 5-HT₃ receptors and strychnine antagonizes some GABA_A receptors. The low selectivity of both alkaloids has been attributed to a limited number of contacts in the ligand-binding pocket (Brams *et al.*, 2011b). Another antagonist displaying no subunit selectivity on Gly receptors is 3-[2'-phosphonomethyl[1,1'-biphenyl]-3-yl]alanine (PMBA). Although structurally distinct, PMBA and strychnine exhibit a number of similarities in their antagonism of recombinant Gly receptors. Therefore, they are assumed to bind to similar and possibly overlapping sites at the receptor (Saitoh *et al.*, 1994).

Picrotoxin (PTX)

In contrast to strychnine and PMBA, picrotoxin (PTX) has been shown to discriminate between homo- and heteromeric Gly receptors (Pribilla *et al.*, 1992). While homomeric $\alpha 1$ and

$\alpha 2$ Gly receptors are blocked at low micromolar concentrations, $\alpha 1\beta$ Gly receptors are relatively resistant to PTX (Lynch *et al.*, 1995). Nevertheless, PTX is not specific for Gly receptors as it also modulates GABA_A receptors. Inhibition by PTX is sensitive to mutations of residues in the ion channel pore (Zhang *et al.*, 1995). However, the possibility that it induces classical pore block seems unlikely. Further studies have revealed that PTX acts in an allosteric mode inducing conformational changes in the M2–3 loop and thereby transmitting glycine-induced conformational changes in the ECD to the channel gate (Hawthorne and Lynch, 2005). In this respect, Wang *et al.* (2006) showed that PTX binds to Gly receptors in the open state and is likely to be trapped while glycine dissociates from the receptor.

Cyanotriphenylborate (CTB)

CTB represents a subunit-selective open-channel blocker of Gly receptors (Rundstrom *et al.*, 1994). The antagonistic

effect of CTB is non-competitive and depends on a single glycine residue at position 254 of the $\alpha 1$ Gly receptor subunit, which is exchanged by an alanine residue in the CTB-resistant $\alpha 2$ subunit. Although positively and negatively modulating agents of the inhibitory Gly receptors exist, with the exception of CTB, there is no known specific blocker of Gly receptors or even a subunit-specific blocker.

Ivermectin

Endogenous neurotransmitter agonists activate rapidly reversible currents at Gly receptors. In contrast, the anthelmintic ivermectin activates slowly developing currents that are usually irreversible (Shan *et al.*, 2001a). There is evidence that binding sites for glycine and strychnine are distinct from that for ivermectin and that different conformational changes are involved in activation by the respective agonists. Ivermectin inserts deeply into the subunit interface, wedged between the M3 α -helix on the principal and the M1 helix on the complementary subunit (Hibbs and Gouaux, 2011). The reversible agonist activity of ivermectin is slow and is most likely due to its accumulation in the membrane associated with weak binding, which induces a global receptor conformational change. The weak interaction might either facilitate agonist binding or agonist-induced conformational changes associated with channel activation.

Alcohols and anaesthetics

Gly receptors are modulated by ethanol and anaesthetics. It has been hypothesized that amino acids in all four transmembrane domains contribute to a drug-binding cavity (Cheng *et al.*, 2008). Using chimeric Gly $\alpha 1$ /GABA $\rho 1$ receptor constructs, a region of 45 amino acids within the M2 and M3 domains of Gly receptors was identified, which appeared to be essential and sufficient for the enhancement of receptor function by ethanol. Within this region, two specific residues, S267 in M2 and A288 in M3, have been found to play a unique role in the allosteric modulation of both GABA $_A$ and Gly receptors by alcohols and anaesthetics (Mihic *et al.*, 1997). Furthermore, hyperekplexia-associated mutations of S267 and neighbouring residues have been found to reduce glycine sensitivity and to convert β -alanine and taurine into competitive antagonists (Rajendra *et al.*, 1995; Becker *et al.*, 2008) (Figure 1; Table 1). The potency of *n*-alcohols on recombinant Gly receptor responses increased with alkyl chain length up to 12 carbon atoms (Mascia *et al.*, 1996). Moreover, anaesthetic concentrations of propofol, an aromatic alcohol, as well as volatile hydrocarbons, such as halothane, enflurane, isoflurane, methoxyflurane and sevoflurane, enhance the effects of low glycine concentrations (Machado *et al.*, 2011; Lee *et al.*, 2013). Molecular models suggest that residues of M2 and M3 surround a water-filled pocket, in which alcohol binding could preferentially stabilize the open state (Cheng *et al.*, 2008; Schaefer *et al.*, 2012). Recently, the X-ray structure of a GLIC mutant was solved in the presence and absence of ethanol and other modulators representing the structural basis for ethanol potentiation of CL receptors (Sauguet *et al.*, 2013). GLIC is a prokaryotic member of the CL receptor family. A mutation in the pore-lining M2 helix F238A (corresponding residues in other CL receptors: F in nACh receptor subunits, Q in Gly receptors, L

in GABA $_A$ subunits) of GLIC resulted in a marked potentiation of function by pharmacologically relevant concentrations of ethanol (Howard *et al.*, 2011). The structural data in the presence of ethanol or anaesthetics suggest a stabilization of the open form of the ion channel while binding to a transmembrane cavity between receptor subunits.

Endocannabinoids and other allosteric modulators

Gly receptor activity can be allosterically modulated by certain endocannabinoids (ECs) in a G-protein independent manner (Hejazi *et al.*, 2006; Yevenes and Zeilhofer, 2011a). Accordingly, chemically neutral ECs (e.g. anandamide) are positive modulators of $\alpha 1$, $\alpha 2$ and $\alpha 3$ Gly receptors, whereas acidic ECs (e.g. *N*-arachidonoyl-glycine, NA-Gly) potentiate only $\alpha 1$ Gly receptors but inhibit $\alpha 2$ and $\alpha 3$. The sites for the EC modulation of Gly receptors are different from the M sites responsible for ethanol modulation and involve a basic residue within the large intracellular loop between M3 and M4 that is also required for G $\beta\gamma$ modulation (Yevenes *et al.*, 2006; Yevenes and Zeilhofer, 2011b). It has recently been proposed that the positive allosteric modulation of Gly receptors exerted by the derivatives of $\Delta 9$ -tetrahydrocannabinol and cannabidiol are highly relevant for cannabinoid-induced analgesia in animal models of pain. Therefore, these ligands could represent a promising strategy for the development of new pain therapeutics (Xiong *et al.*, 2011; 2012).

Curcuminol, another allosteric modulator of the Gly receptor, is one of the two sesquiterpenes present in the volatile essential oil of *Rhizoma curcumae*. This compound inhibits glycine-mediated currents reversibly and in a concentration-dependent manner. The most prominent effect was observed on $\alpha 2$ homomers and $\alpha 2\beta$ heteromers. Site-directed mutagenesis identified T59 in the ECD of $\alpha 2$ that confers curcuminol sensitivity. When T59 was exchanged by an A, as present in the $\alpha 1$ or $\alpha 3$ subunit (A52), the curcuminol effect was almost absent. However, the inhibitory effect of curcuminol can be transferred to $\alpha 1$ or $\alpha 3$ carrying a threonine instead of an alanine 52 (Wang *et al.*, 2012). The exact mechanism of curcuminol's action is still unclear and needs further investigation.

Sesterterpenes isolated from Australian sponges of the genus *Psammocinia* represent a new class of Gly receptor modulators. Electrophysiological recordings on stable transfected HEK293 cell lines expressing either the $\alpha 1$ or the $\alpha 3$ Gly receptor subunits revealed that (–)-ircinianin, (–)-ircinianin lactam A sulphate and (–)-oxoircinianin lactam A react preferentially with the $\alpha 1$ subunit, whereas (–)-ircinianin lactam A was specific for the $\alpha 3$ subunit (Balansa *et al.*, 2013a; b).

Glycine receptor mutants and human hyperekplexia

Following the identification of *GLRA1* as a candidate gene associated with hyperekplexia and the cloning of Gly receptor subunits from human samples, the consequences of known *GLRA1* mutations have been analysed *in vitro*. Most of the dominant mutations accumulate in the ion channel domain M2 as well as adjacent loop structures (Figure 1).




Figure 3

Recessive hyperekplexia mutants have disordered trafficking and protein stability (modified from Villmann *et al.*, 2009b). Comparison of cell surface and intracellular protein of recessive Gly receptors $\alpha 1$ subunit variants from transfected COS7 cells. (A) Quantified reduced surface expression of Gly receptors $\alpha 1$ mutants (14–50% of wt expression) is evident from labelled surface proteins by NHS-SS-biotin. (B) Cell surface expression was less in non-permeabilized transfected HEK293 cells using the monoclonal anti-Gly receptor $\alpha 1$ antibody mAb2b. While M1-mutants (I244N, S231R) are still expressed at the cell surface, only some antigenic clusters were observed for the arginine mutants R252Q and R392H (lower pictures). (C) Protein stability of Gly receptor $\alpha 1$ subunit mutants analysed by pulse-chase radiolabelling. The radiolabelled mutants from transfected HEK293 cells were immunoprecipitated with the monoclonal antibody mAb2b. The intensities of radiolabelled Gly receptor $\alpha 1$ receptor bands from independent experiments ($n = 3$) were quantified using the Image Quant software (Molecular Dynamics). Wild-type $\alpha 1$ protein and mutants displayed obvious differences in membrane accumulation and half-life of radiolabelled protein. Protein band of 48 kD and intermediate bands (35 kD) are shown. The dashed lines marked by an asterisk (*) indicate the first appearance of the lower MW Gly receptor $\alpha 1$ protein band at 35 kD.

Their close location to the ion channel pore suggests that these mutations might change ion channel properties. Human mutations such as P250T, Q266H, S267N, R271Q/L, K276E and Y279C showed reduced maximal glycine-induced currents, decreased open probability and reduced glycine sensitivity (Lynch *et al.*, 1997; Saul *et al.*, 1999; Chung *et al.*, 2010) (Table 1). For some dominant mutants, reduced surface expression was also observed. No changes in glycine binding, but less taurine binding, were observed for V260M, which is localized in the inner ion channel (del Giudice *et al.*, 2001). Furthermore, mutations I244N and P250T have been described, which lead to an enhanced desensitization of the Gly receptor channel. Residues I244 and P250 are localized at the end of M1 or within the loop between M1–M2 at the cytoplasmic side of the membrane (Lynch *et al.*, 1997; Breiteringer *et al.*, 2001) (Figure 2). These data support the

proposal that the intracellular structural domains are involved in the modulation of ion channel properties such as desensitization.

Recessive hyperekplexia due to mutations in the *GLRA1* or *GLRB* gene are more dispersed over all the Gly receptor subunits (Figure 1). Among the ECD mutants, most variants show disturbances in assembly and trafficking to the cell surface (Chung *et al.*, 2010; 2013; James *et al.*, 2013). As a result, their surface expression is reduced or absent. However, there are exceptions such as M1 mutants; S231R and I244N are transported but exhibit highly reduced maximal glycine-gated currents (Lynch *et al.*, 1997; Humeny *et al.*, 2002; Villmann *et al.*, 2009b) (Figure 3). Intracellular arginine mutations are also associated with recessive hyperekplexia (Vergouwe *et al.*, 1999; Rea *et al.*, 2002). Residues R252 and R392 are located next to M2 or M4 and seem to play an

important role as topological start or stop signals for the membrane integration of the appropriate M domains. Mutations of these arginines almost completely inhibit their expression at the cell surface and they accumulate in the ER, where they undergo proteasomal degradation. Their co-expression, together with the Gly β receptor subunit, was not able to circumvent this process. Furthermore, recessive hyperekplexia mutants display a higher turnover rate and are unstable compared to wild-type $\alpha 1$ Gly receptor protein (Figure 3). Degradation of mutated $\alpha 1$ proteins was faster by around a factor of 5 for M1 mutants (S231R and I244N; 9 and 3 h compared to 24 h for the wild type) but 20-fold faster for intracellular arginine mutations R252H and R392H (Villmann *et al.*, 2009b) (Table 1).

From studies on human patients, *GLRB* has only rarely been found to be a target gene for hyperekplexia (Filatov and White, 1995; Shan *et al.*, 2001b; Rees *et al.*, 2002). Three novel amino acid substitutions M177R, L285R and W310C have recently been reported in patients with hyperekplexia, demonstrating that *GLRB* is the third most common gene associated with hyperekplexia in humans (Chung *et al.*, 2013; James *et al.*, 2013). Similar to the effects observed with $\alpha 1$ mutations, these substitutions affect the physiology of the ion channel. The $\alpha 1/\beta$ M177R Gly receptors were demonstrated to have increased EC₅₀s and decreased maximal responses. The Gly receptors composed of $\alpha 1/\beta$ L285R display a leak conductance associated with spontaneous Gly receptor activity. These data again show that the Gly receptor β subunit is not only a structural component of the receptor complex via its binding to the scaffolding protein gephyrin, but these β residues are important for the characteristic properties of the Gly receptor channel.

Hyperekplexia-like phenotypes in mice with glycine receptor mutations

The genetic causes underlying hyperekplexia-like phenotypes in different mouse models were determined in the early 1990s after successful cloning of the Gly receptor subunits from mice. *Spasmodic* (*spd*), *oscillator* (*spd^{ot}*) and *spastic* (*spa*) are spontaneous mouse mutants with mutations either in the *Gla1* or *Glrb* gene (Keramidas *et al.*, 2004). A normal life expectancy was only observed for homozygous *spasmodic* animals. These mice carry a point mutation A52S in the ECD of the $\alpha 1$ Gly receptor protein, leading to a reduced affinity for glycine (Ryan *et al.*, 1994; Saul *et al.*, 1994) (Table 2). Physiological characterizations of these mutant receptors on hypoglossal motoneurons from *spd/spd* animals showed reduced mIPSC amplitudes but significantly faster decay times compared with control mIPSCs. However, the single channel open probability was unchanged (Graham *et al.*, 2006). These slight changes in ion channel properties in *spasmodic* mice are in line with the observed mild hyperekplexia-like phenotype; these mice display exaggerated startle responses after touching but have a normal life expectancy. In contrast, *spastic* and *oscillator* mice show a much more severe phenotype. *Oscillator* affects the *Gla1* gene (Figure 4; Table 2). Homozygous *oscillator* mice do not survive the third post-natal week. At the molecular level, a microdeletion together with a microinsertion generated a 7 bp frameshift deletion, resulting in a functional null mutation. Consistent with the non-sense mutation, two different transcripts are formed dependent on the use of an alternative splice acceptor site 3' to the

Table 2

Mutations in mice

Name gene mutation	Mode of mutation	Mode of inheritance	Effect	References
<i>Spasmodic Gla1</i> A52S	Spontaneous	Autosomal recessive	Decrease in glycine affinity	Ryan <i>et al.</i> (1994); Saul <i>et al.</i> (1994)
<i>Nmf11 Gla1</i> N46K	ENU-induced	Autosomal recessive	No physiological data	Traka <i>et al.</i> (2006)
<i>Gla1</i> D80A/G	Knock-in	Autosomal recessive	Selective loss of synaptic Zn ²⁺ potentiation	Hirzel <i>et al.</i> (2006)
<i>Cincinnati Gla1</i> F159X	Spontaneous	Autosomal recessive	Loss of function	Holland <i>et al.</i> (2006)
<i>Gla1</i> Q266I	Knock-in	Autosomal recessive	Reduced functionality of Gly receptors	Blednov <i>et al.</i> (2012); Borghese <i>et al.</i> (2012)
<i>Gla1</i> S267Q	Transgene and knock-in	Autosomal recessive	No enhancing effects with ethanol	Findlay <i>et al.</i> (2002; 2005)
<i>Gla1</i> R271Q	Transgene	Autosomal recessive	Decrease in glycine affinity	O'Shea <i>et al.</i> (2004)
<i>Gla1</i> M287L	Knock-in	Autosomal recessive	Reduced functionality of Gly receptors	Blednov <i>et al.</i> (2012); Borghese <i>et al.</i> (2012)
<i>Oscillator Gla1</i> ins/del P327X	Spontaneous	Autosomal recessive	Loss of function	Buckwalter <i>et al.</i> (1994); Kling <i>et al.</i> (1997); Villmann <i>et al.</i> (2009a)
<i>Spastic Glrb</i> LINE1 insertion	Spontaneous	Autosomal recessive	Less full-length Gly receptor β	Kingsmore <i>et al.</i> (1994); Mulhardt <i>et al.</i> (1994); Becker <i>et al.</i> (2012)



Figure 4

Phenotype of a homozygous *oscillator* (*spd^{ot}/spd^{ot}*) mouse compared with a wild-type control littermate (+/+). *Oscillator* mice are usually smaller than wild-type controls. Shown are animals at post-natal day (P)19. The *oscillator* mutant usually dies by P21. Symptoms start around P15 and develop progressively during P17–P21. Rigidity of the whole body and massive tremor in forelimbs, hindlimbs and even the tail are seen compared with a healthy control mouse.

mutation. If the splice acceptor site is used, a 24 bp shorter transcript is generated. However, at the protein level, a non-sense protein is formed, which is longer than the normal wild-type protein. If the splice acceptor site is not used, a short truncated protein is generated with an early stop codon within the 8 amino acids encoded by the alternative splicing cassette in the M3–M4 loop of $\alpha 1$ Gly receptor (Malosio *et al.*, 1991). In *in vitro* recordings from transfected cells, it was found that both splice variants had similar physiological properties. $\alpha 1$ Gly receptor proteins have never been detected in homozygous *oscillator* animals, most probably due to non-sense-mediated decay mechanisms (Kling *et al.*, 1997; Villmann *et al.*, 2009a).

The $\alpha 3$ splice variants are also generated by alternative splicing in the M3–M4 loop, resulting in fast desensitizing currents for the short variant Gly receptor $\alpha 3K$ and non-desensitizing currents for the long splice variant Gly receptor $\alpha 3L$. Both variants differ in the absence or presence of an intracellular, 15 amino acids-long, alternative splice cassette in the M3–M4 loop. Mutations within this splice cassette of the Gly receptor $\alpha 3$, its deletion or duplication further confirmed these findings (Nikolic *et al.*, 1998; Breitingner *et al.*, 2009). In contrast to $\alpha 3K$, the $\alpha 3L$ variant has been shown to be more mobile and is able to cluster in hippocampal neurons. In addition, *in vivo* the $\alpha 3L$ variant is usually predominant in the brain. A redistribution of $\alpha 3L$ towards $\alpha 3K$ due to post-transcriptional processing seems to be associated with some forms of mesial temporal lobe epilepsy (Eichler *et al.*, 2009; Notelaers *et al.*, 2012).

The Gly receptor $\alpha 1$ is the most important α subunit at post-natal stages. During embryogenesis, the $\alpha 2$ subunit is prominent, most probably generating homomeric Gly receptor pentamers. After birth between P5 and P14, the $\alpha 2$ subunit is down-regulated and the appearance of $\alpha 1$ increases continuously. Similar time frames have been described for the transformation of mixed GABA/glycine synapses into glycinergic presynaptic terminals in many spinal and brainstem synapses in wild-type mice (Jonas *et al.*, 1998; Kotak *et al.*, 1998; Muller *et al.*, 2006). Postsynaptic Gly receptor complexes present after this stage of development are mainly composed of $\alpha 1/\beta$ subunits. *In vivo* electrophysiological recordings on superficial dorsal horn neurons, which concentrated on compensatory mechanisms by other Gly receptor subunits, showed that there are remaining functional $\alpha 3/\beta$ complexes (Graham *et al.*, 2006; 2011). Nevertheless, in the *oscillator* mice these $\alpha 3/\beta$ complexes are not sufficient to sustain life.

The *spastic* mouse mutant is, as yet, the only known Gly receptor β mutation in rodents (Becker *et al.*, 1986; Kingsmore *et al.*, 1994; Mulhardt *et al.*, 1994). At the molecular level, two independent groups found that the underlying cause was an insertion of a transposable LINE1 element into intron 6 of the *Glr*b gene (Kingsmore *et al.*, 1994; Mulhardt *et al.*, 1994). The consequences of this LINE1 insertion are skipping of exons 5 and 6 or both. Therefore, much less full-length Gly receptor β protein is available for the formation of postsynaptic $\alpha 1/\beta$ Gly receptor complexes in adult homozygous *Glr^b^{spa/spa}* mice (Keramidas *et al.*, 2004; Becker *et al.*, 2012). These highly reduced functional $\alpha 1/\beta$ Gly receptor complexes are the underlying reason for the hyperekplexia-like phenotype in *spastic* mice.

Recently, it has been shown that the *spastic* allele of the murine *Glr*b is a two hit mutation. The original *spastic* mutation was demonstrated in a hybrid mouse background B6C3Fe. A minigene approach using DNA from both parental backgrounds C57BL/6J and C3H/HeJ of *Glr*b wild-type and *spastic* animals identified a single nucleotide polymorphism in exon 6 between both mouse backgrounds. Thus, the disturbed splicing pattern of *Glr*b is not only a result of the LINE1 insertion but is also due to a SNP that disrupts an exonic splicing enhancer (ESE) sequence within exon 6 leading to missplicing. The ESE is important for the binding of an essential splicing regulatory protein SFRS1 (Becker *et al.*, 2012).

These data indicate that in addition to a mutation in a disease-associated gene the mouse background might also have an effect on the observed neuromotor phenotype. Similar findings have been obtained in other mouse models of movement disorders, for example, ataxia, dystonia, tremor and progressive paralysis, are associated with mutations in the *Scn8a* gene encoding a widely distributed voltage-gated sodium channel (Buchner *et al.*, 2003).

Two other Gly receptor mutations in mice have been described. The *cincinnati* mouse possesses a premature stop codon (F159X) representing another example of a functional null mutation (Holland *et al.*, 2006). An ENU-induced mutation N45K localized in the ECD of the Gly receptor $\alpha 1$ protein has been identified and although it has not been characterized at the physiological level (Traka *et al.*, 2006), it was hypothesized that due to the close localization of N45K to A52 (*spasmodic*), this mutation might also affect glycine affinity.

Studies on the spontaneous mouse mutants have provided lots of details on the effects of alterations in the mechanisms of inhibitory neuronal circuits in rodents. In turn, that allowed us to draw conclusions for the human situation in various types of hyperekplexia. The top-down approaches using knock-out and knock-in mouse models carrying human mutations have helped to relate and understand the consequences of the human variants on channel physiology *in vivo*.

R271 mutations: the first knock-in mouse models

The R271Q/L mutations were discovered in human hyperekplexia patients by Shiang *et al.*; R271 is located in the M2–M3 loop close to the ion channel pore (Shiang *et al.*, 1993). *In vitro* experiments by Langosch and Rajendra demonstrated that the mutations at position 271 do not alter ligand binding to glycine, but do significantly affect binding of β -alanine and taurine (Langosch *et al.*, 1994; Rajendra *et al.*, 1994; 1995). Laube *et al.* (1995b) demonstrated that an iso-functional substitution of R271K led to reduced affinities and maximal current responses (I_{\max}) following application of the low-efficacy agonists β -alanine and taurine. All data on R271 substitutions suggest that it is associated with a highly diminished agonist sensitivity without differences in agonist affinity. From the *in vitro* data, it was concluded that ligand binding in R271 is uncoupled from the channel activation mechanisms.

An introduction of R271Q by a transgenic approach into mice generated tg271Q animals with a hyperekplexia-like phenotype even in heterozygous animals. Like *spastic* mice, homozygous tg271Q animals did not reach adulthood. It should be noted that the symptoms were gene dose-dependent and strains with the lowest expression rate did not develop any phenotype (Becker *et al.*, 2002). Notably, an inter-cross of tg271R into *sp^d* mice could prevent the lethal phenotype of the *oscillator* loss-of-function mutation. This suggested that the tg271R enabled the formation of functional interspecies Gly receptor complexes in *sp^d* mice (Becker *et al.*, 2002).

O'Shea *et al.* (2004) successfully restored the function of R271Q/L with the help of propofol in *in vitro* experiments and also in a mouse model *in vivo*. The maximal glycine-induced currents of oocytes transfected with R271Q and R271L were markedly potentiated in the presence of propofol, whereas the wild-type maximal currents were not affected. In addition, tg271Q mice were tested before and after propofol treatment for startle reaction and righting reflexes. The startle responses of propofol-treated tg271Q mice were temporarily highly reduced and resembled those of wild-type mice. However, within 30 min after injection of propofol, the hyperekplexia-like phenotype reappeared. The same was observed for the righting time of propofol-treated tg271Q mice (O'Shea *et al.*, 2004). Therefore, propofol might be a treatment for human hyperekplexia as it also enhances GABA_A receptor activity in addition to glycine-gated current enhancement, but propofol also possesses anaesthetic and sedative properties.

Other knock-in mice to study the modulation by *n*-alcohols

Humans produced and consumed alcohol even a millennia ago. Nowadays, alcohol is the most widely used drug worldwide (Vallee, 1998). However, the mechanism by which alcohol acts on ion channels is still unclear.

A huge step towards discovering the effect of ethanol on the Gly receptor was carried out by Mihic *et al.* (1997). With the creation of various chimeric receptor constructs, a 45 amino-acid region was found to be necessary and sufficient for the enhancement of receptor function in the presence of ethanol. S267 and A288 turned out to be critical for the modulatory action of ethanol. The mutated receptors harbouring S267I did not enhance receptor function (Mihic *et al.*, 1997). It was found that A288 has a critical role in the pharmacology of Gly receptors and this residue contributes to the binding cavity for *n*-alcohols and volatile anaesthetics (Lobo *et al.*, 2008). Ethanol was also demonstrated to inhibit strychnine-induced seizures in mice (McSwigan *et al.*, 1984). But it is not known how or whether the behavioural effects of ethanol are linked to the potentiation of Gly receptor function.

To determine this, a mouse line carrying a S267Q transgene under the control of the rat synapsin 1 promoter was created. S267Q showed normal sensitivity to glycine and no enhancing effects in the presence of ethanol. Moreover, high concentrations of ethanol inhibited the function of this mutant receptor *in vitro*. The ability of ethanol to eliminate strychnine-induced seizures was reduced in transgenic mice, which is in line with earlier reports (Findlay *et al.*, 2002). In three behavioural tests, a decreased sensitivity to ethanol was observed: (i) ethanol inhibition of strychnine-induced seizures; (ii) motor incoordination (rotarod); and (iii) loss of righting reflex (LORR). One disadvantage of mice carrying the mutation S267Q on a transgene was that they still had endogenously expressed, alcohol-sensitive wild-type Gly receptors. Therefore, the generation of S267Q knock-in mice was required.

Homozygous S267Q knock-in mice exhibit a hyperekplexia-like phenotype and like *sp^d* mice die by 3 weeks of age. Compared to the wild-type mice, no differences in Gly receptor expression were detectable in S267Q knock-in mice. However, the observed decrease in maximal responses to glycine and the decreased ion influx suggested a disruption of ion channel function (Findlay *et al.*, 2003). From the results of NMR studies, it was postulated that S267Y stabilizes the closed state of the inhibitory Gly receptor (Tang *et al.*, 2002), which could explain the reduced open channel time and the observed decrease in potency of glycine in S267Q mice.

In summary, S267 is involved in the effects of alcohols and volatile anaesthetics and seems to be part of a binding site for these modulators. These findings strongly suggest that S267 is also involved in channel gating. Further support came from a human mutation S267N, which was found in a patient suffering from hyperekplexia. In electrophysiological studies in transfected HEK293 cells, the S267N mutation resulted in an increased EC₅₀ for glycine, but no changes in I_{\max} values (Becker *et al.*, 2008). Although S267 lies in an

alcohol-sensitive domain, no alterations in alcohol sensitivity were apparent in transfected HEK293 cells, the effect of alcohol was visible only when this mutation was expressed in *Xenopus* oocytes (Valenzuela *et al.*, 1998; Findlay *et al.*, 2003). These findings provide further evidence that the Gly receptor M2 domain is sensitive to alcohol.

In order to generate a knock-in mouse to elucidate the effects of alcohol on Gly receptors, it is necessary to use a model where Gly receptor function is generally unaffected. Two other candidates from previous *in vitro* experiments were Q266I and M287L (Mihic *et al.*, 1997). Here, channel properties of mutated Gly receptors expressed in *X. laevis* oocytes and HEK293 cells were similar to those observed in recordings from isolated neurons and membrane preparations from corresponding knock-in mice. Heterozygous as well as homozygous animals revealed decreased glycine-induced maximal currents and a lack of sensitivity to ethanol suggesting a reduced functionality of Gly receptors in both knock-in models (Borghese *et al.*, 2012). In turn, strychnine sensitivity was increased. The single-point mutations Q266I and M287L resulted in the death of homozygous mice during the third post-natal week. Moreover, in behavioural studies, heterozygous mice displayed an increased startle response. In these mice, five behavioural experiments have been performed in which the effects of alcohol were reduced compared with the wild-type mice: (i) acute alcohol withdrawal; (ii) ethanol induced LORR; (iii) alcohol consumption; (iv) recovery from rotarod ataxia; and (v) alcohol-induced taste aversion. Taken together, these data show that the Q266I mutation produced a much higher suppression of alcohol action than the M287L mutation (Blednov *et al.*, 2012).

In conclusion, structural data and transgenic mouse models demonstrate that ethanol acts via an inter-subunit cavity close to the M2–M3 regions, thereby stabilizing the open channel conformation.

D80A knock-in mice: the first *in vivo* evidence for Zn^{2+} modulation of ligand-gated glycine receptor channels

Zn^{2+} modulation is important in many neurological signal transduction pathways. Data from *in vitro* studies on Zn^{2+} modulation have identified residues within the Gly receptor $\alpha 1$ subunit responsible for potentiating as well as inhibitory effects of Zn^{2+} . A knock-in mouse mutant D80A with a disruption of the high-affinity Zn^{2+} binding site was generated to study Zn^{2+} neuromodulation *in vivo*.

Interestingly, D80A knock-in mice develop a hyperekplexia-like phenotype, which persists into adulthood and have a normal lifespan and fertility. In electrophysiological studies of spinal cultures and brainstem slices, a reduction in the Zn^{2+} -mediated potentiation of Gly receptors with no changes in its basic functions was detected. These mice showed an increase in b-wave amplitudes of the ERG (electroretinogram), which is a parameter for visual signal processing and an enhanced ASR (acoustic startle response). This also indicates deficits in the development of sensory transmission and auditory circuits.

From the various results it was concluded that the phenotype of D80A mice is due to a selective loss of synaptic Zn^{2+} potentiation. In heterozygous expression experiments, D80A does not alter the glycine dose–response relationship, open probability and single channel conductance (Laube *et al.*, 1995a; 2000). This was also apparent in recombinant $\alpha 1^{D80A}\beta$ Gly receptors and homozygous *Gla1* (D80A) neurons. There was no change in synaptic localization in spinal cord neurons from homozygous animals. Glycinergic IPSCs, decay kinetics and frequencies were similar in cultured spinal cord neurons and P8 brainstem hypoglossal motoneurons from wild-type and D80A animals. Changes occurred first in hypoglossal motoneurons at P14 with reduced amplitudes and shorter decay time. This onset fits with the developmental change of the embryonic Gly receptor isoform $\alpha 2$ towards the adult isoform composed of $\alpha 1$ and β subunits. Zn^{2+} seems to play an important role in glycinergic neurotransmission in the context of normal behaviour (Hirzel *et al.*, 2006). Further support for a critical role of zinc in the modulation of Gly receptor function came from an *in vivo* study on heterozygous D80A mice, in which zinc binding and ethanol modulation were investigated. Knock-in female mice have been found to consume less ethanol, demonstrate a decreased preference for alcohol and have an increased startle response, in agreement with previous findings for sex differences in alcohol consumption (Blednov *et al.*, 2012; McCracken *et al.*, 2013). These data emphasize the important role of residue D80 for both zinc binding and modulation of ethanol actions *in vitro* and *in vivo*.

Domain co-expression: a way to rescue protein function

Gly receptors are composed of independent folding domains. This has been shown in a series of rescue of function experiments with the non-functional truncated $\alpha 1$ variant present in the mouse model *oscillator*. The *oscillator* mutation is a frameshift mutation. Depending on which alternative splice acceptor site is used, two transcript variants are generated, leading to either a truncated or an elongated protein. *In vitro* experiments showed a non-functionality of both proteins lacking most of the M3–M4 loop, M4 and the C-terminus. If the portion of the $\alpha 1$ protein lacking was co-expressed as a second independent domain, Gly receptor function was restored *in vitro* (Villmann *et al.*, 2009a) (Figure 5A).

Reorganization of domains was a significant factor in the evolution of prokaryotic channels and has been described as being important for the distribution of prokaryotic members of the ACh receptor family (Li *et al.*, 2006). Such rearrangements of known protein domains from prokaryotes or other less developed species were most probably an evolutionary advantage for the generation of eukaryotic proteins with novel functions. The class of excitatory glutamate (Glu) receptors evolved from protein domains of other origin. Here, domain exchange between an ancestral Glu receptor channel pore Glu receptor 0 into another donor receptor GluK2 generated functional ion channels (Hoffmann *et al.*, 2006). Studies on a functional chimera with the ECDs from the prokaryotic CL receptor GLIC (*Gloeobacter violaceus*) and the




Figure 5

Domain complementation for rescue of ion channel function (modified from Unterer *et al.*, 2012 and Villmann *et al.*, 2009a). (A) Rescue of function experiments of the truncated *oscillator* Gly receptor $\alpha 1$ variant *spd^{ot}* compared with truncated wild-type $\alpha 1$. When single domains of the Gly receptor $\alpha 1$ were expressed, no functional channels were observed following 3 mM glycine application (upper panel). If the complementation domain (N-myc tail) was co-expressed, functional rescue was observed for the truncated wild type and the *oscillator* Gly receptor $\alpha 1$ variants (middle and lower panel). (B) Comparison of infected (DIV21; bottom) and uninfected spinal cord neurons isolated from either homozygous wild type (+/+) or *oscillator* (ot/ot) mice (DIV21 uninfected) with the N-myc tail construct encoded on a pAAV vector. Infected neurons show a signal for the endogenous Gly receptor $\alpha 1$ protein (bottom 3 panels, right picture specific Gly receptor $\alpha 1$ signal in red) that co-localized (merged pictures) with the N-myc tail complementation domain. (C) Functionality of the Gly receptor $\alpha 1$ expressed from three domains. The functionality of the truncated N-terminal domain of the Gly receptor $\alpha 1$ ($\alpha 1$ -trc) was not restored by either the M3–M4 loop or the shortened complementation domain (myc-iD Δ 62-TM4). Co-expression of all three domains restored Gly receptor function (middle trace).

M-domains of Gly receptor $\alpha 1$ showed that both domains contributed to the physiological properties of the generated chimeric channels. The chimera could be activated by protons, a prerequisite of GLIC but also harbours properties of the human Gly receptor $\alpha 1$ such as the allosteric modulation by propofol (Duret *et al.*, 2011).

The special feature in the rescue of function experiments is that the domains are separately expressed and not connected like chimeric proteins. Similar to the complementa-

tion of *oscillator* domains, for 7-TM receptors it has been shown that domains of the GPCRs fold independently, for example, the vasopressin receptor V₂ and the muscarinic ACh receptor (Schoneberg *et al.*, 1995; 1996).

A functional rescue of Gly receptor function was not only shown *in vitro* in transfected cell lines. Following an infection of the rescue domain via a viral construct into primary spinal cord neurons isolated from homozygous *oscillator* animals, the Gly receptor $\alpha 1$ protein, which has never been detected in

uninfected neurons, was up-regulated (Villmann *et al.*, 2009a) (Figure 5B). Usually *oscillator* mice die during the third week after birth and a lack of expression of the Gly receptor $\alpha 1$ protein is the underlying reason for this (Buckwalter *et al.*, 1994; Kling *et al.*, 1997). With the help of an independent rescue domain, it appears to be possible to overcome the non-functionality of truncated receptor variants. Nevertheless, *in vivo* data are still missing in this context. Using the *in vitro* rescue of function experiments, several domains have been identified that are important for trafficking of Gly receptor domains as well as rescue effectiveness (Unterer *et al.*, 2012). At the 3' sequence to the *oscillator* mutation, the wild-type harbours a basic motif RRKRR in the M3–M4 loop. These residues have been demonstrated to ensure the cell surface expression of the $\alpha 1$ protein (Sadtlir *et al.*, 2003). When RRKRR was introduced into the *oscillator* GDIT sequence, the rescue efficiency was increased from 10% towards wild-type responses (100%). Studies on intracellular basic residues, which are affected in hyperekplexia patients showed the importance of these positively charged residues for protein biogenesis and function (Rea *et al.*, 2002; Villmann *et al.*, 2009b).

To gain further insights into the mechanisms of functional rescue by independent domains, *in vitro* studies on truncated rescue domains have been performed. Truncation from the N-terminus corresponding to residues in the beginning of the M3–M4 loop generated functional channels when co-expressed with a truncated $\alpha 1$ wild-type up to a deletion of 49 amino acid residues of the M3–M4 loop (the last with a rescue efficiency of 58%). Further deletions generated almost no functional chloride channels (Unterer *et al.*, 2012). The M3–M4 loop is the most highly variable among all the CL receptor members. The Gly receptor M3–4 loop can be divided into variable (V) and conserved (C) regions (Melzer *et al.*, 2010; Unterer *et al.*, 2012). The conserved region C3 seems to act as a barrier between functional and non-functional complementation in a two domain Gly receptor configuration. C3 is localized before M4 and harbours a high number of charged residues. Large truncations of the M3–M4 loop deleted all negatively charged residues and generated positively charged N-terminal ends. Ionic interactions between positively and negatively charged residues in the M3–M4 loop might represent the mechanism that mediates the rescue of Gly receptor function from independent domains. It is striking that all charged residues are localized in conserved regions in human, rat and mouse Gly receptor α subunits ($\alpha 1$ – $\alpha 4$). Moreover, it is known that the last aspartate in front of M4 is conserved in 45 known CL receptor subunits. This aspartate is required for GABA_A receptor assembly as its mutation resulted in ER accumulation and thus reflects impaired forward trafficking (Rampon *et al.*, 1996). Hence, an interaction between charged residues in the M3–M4 loop could also be required for the transduction of conformational changes of the whole Gly receptor protein translating ligand binding into opening and closing of the ion channel. The Gly receptor domain architecture does also allow for the generation of a functional inhibitory neurotransmitter receptor from three independent domains. The co-expression of the lacking M3–M4 loop in addition to the truncated N- and C-terminal Gly receptor $\alpha 1$ protein fragments again resulted in the rescue of channel function (Figure 5C) (Unterer *et al.*, 2012).

The domain study demonstrated that the concomitant transport of Gly receptor subdomains covering the entire Gly receptor subunit sequence passes the ER control system; otherwise, most of the truncated Gly receptor domains accumulate in the ER compartment and get degraded similar to the assembly of the nACh receptor from different subunits (Villmann *et al.*, 2009a; Valkova *et al.*, 2011). These extensive studies that use domain complementation as a way of producing functional protein rescue suggest novel strategies for gene-therapeutic approaches.

Conclusions and perspectives

The inherited neuromotor disorder hyperekplexia is associated with mutations in glycine receptor genes, genes encoding for Gly receptor interacting proteins or even the presynaptic glycine transporter 2. Gly receptors are most important for inhibitory neurotransmission in the adult spinal cord and brainstem in humans and in rodents. Dysfunction of these receptors in humans results in startle attacks and excessive muscle tremor induced by tactile or acoustic stimuli. Interestingly, similar phenotypes have been detected in mice carrying mutations in the *Gla1* or *GlrB* genes. Characterization of the spontaneous mouse models *spasmodic*, *spastic* and *oscillator* has provided lots of detailed information on the single-channel properties from homozygous but also from heterozygous animals. With the use of protein biochemical techniques, it was possible to show that in mutant mice adaptation processes at the presynapse occur. Here, mixed GABA/glycine vesicles change to GABAergic vesicles, in contrast to the normally occurring developmental shift to presynaptic glycinergic vesicles in brainstem neurons of wild-type mice.

The continuous increase in solved X-ray structures from various members of the CL receptor superfamily has helped to explain the data obtained *in vitro* and *in vivo*. Modern knock-in techniques have enabled the study of human mutations in mice. All single-point mutations known from human mutations have led to hyperekplexia-like phenotypes when introduced into mice. Homozygous animals died 3 weeks after birth similar to the spontaneous mouse mutant *oscillator*. At this developmental stage, the change from the embryonic Gly receptor to the adult isoform should be completed. Knock-in mice indicated the phenotype but have also been used to demonstrate the distinct pharmacological and therapeutic profiles. Clonazepam is the drug of choice for hyperekplexia patients. Unfortunately, in mice clonazepam has only a small therapeutic window where the positive modulation induced by an enhanced GABAergic response helps to improve the hyperekplexia-like symptoms. All efforts to show an up-regulation in the number of GABA receptors as a response to the treatment have failed so far. The mechanism behind clonazepam's action is still not completely understood; an increase in the GABAergic response by a factor of 1.5 at the molecular level seems unlikely to be the only reason for the improvement in symptoms. Other *in vivo* data demonstrated that although $\alpha 3\beta$ receptors are present and functional in $\alpha 1$ mutant mice, these receptors are not sufficient to prevent homozygous mutant mice from dying after 3 weeks of age nor do they rescue the disturbed ion channel

function in heterozygous animals. Furthermore, in human patients, symptoms become less severe when the patients become 3 years old. How the pathomechanism underlying hyperekplexia are able to change with age has to be elucidated. An appropriate mouse model to study this ageing phenomenon would help to further understand the pathology of the neuromotor disorder hyperekplexia.

Functional rescue experiments using domain co-expressions are helpful tools for testing the mechanisms behind truncated receptor variants. One of the first conclusions obtained from these experiments was that Gly receptors could have evolved from independent domains from other origins. Secondly, postsynaptic receptors get assembled in the ER and are concomitantly transported to the cell surface. Thirdly, glycine receptors are not the only truncated receptor variants known to be associated with neurological disease. Null mutations of the GABA γ 2 subunit, another member of the CL receptor superfamily, have been reported in patients suffering from a special form of epilepsy, GEFS+. A functional rescue by domain co-expression might represent a gene-therapeutic strategy to overcome a neurological phenotype. Hence, it has been shown that similar to the Gly receptor, ion channel function can be restored by independent co-expression of receptor domains. However, there is still a lack of evidence for the successful rescue of Gly receptor function *in vivo*.

Acknowledgements

Our research was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) VI586 to C. V.), Johannes and Frieda Marohn Stiftung and EU Neurocypres. We would like to thank the Graduate School of Life Science (GSLS) Würzburg for support of N. S. and G. L.

Conflict of interest

The authors declared that they have no conflict of interest.

References

- Akabas MH, Kaufmann C, Archdeacon P, Karlin A (1994). Identification of acetylcholine receptor channel-lining residues in the entire M2 segment of the alpha subunit. *Neuron* 13: 919–927.
- Al-Futaisi AM, Al-Kindi MN, Al-Mawali AM, Koul RL, Al-Adawi S, Al-Yahyaee SA (2012). Novel mutation of GLRA1 in Omani families with hyperekplexia and mild mental retardation. 46: 89–93.
- Alexander SP, Mathie A, Peters JA (2011). Guide to receptors and channels (GRAC), 5th edn. *Br J Pharmacol* 164 (Suppl 1): S1–324.
- Andermann F, Keene DL, Andermann E, Quesney LF (1980). Startle disease or hyperekplexia: further delineation of the syndrome. *Brain* 103: 985–997.
- Balansa W, Islam R, Fontaine F, Piggott AM, Zhang H, Xiao X *et al.* (2013a). Sesterterpene glycinyl-lactams: a new class of glycine receptor modulator from Australian marine sponges of the genus *Psammocinia*. *Org Biomol Chem* 11: 4695–4701.
- Balansa W, Islam R, Gilbert DF, Fontaine F, Xiao X, Zhang H *et al.* (2013b). Australian marine sponge alkaloids as a new class of glycine-gated chloride channel receptor modulator. *Bioorg Med Chem* 21: 4420–4425.
- Becker CM, Hermans-Borgmeyer I, Schmitt B, Betz H (1986). The glycine receptor deficiency of the mutant mouse spastic: evidence for normal glycine receptor structure and localization. *J Neurosci* 6: 1358–1364.
- Becker K, Hohoff C, Schmitt B, Christen HJ, Neubauer BA, Sandrieser T *et al.* (2006). Identification of the microdeletion breakpoint in a GLRA1 null allele of Turkish hyperekplexia patients. *Hum Mutat* 27: 1061–1062.
- Becker K, Breiting HG, Humeny A, Meinck HM, Dietz B, Aksu F *et al.* (2008). The novel hyperekplexia allele GLRA1(S267N) affects the ethanol site of the glycine receptor. *Eur J Hum Genet* 16: 223–228.
- Becker K, Braune M, Benderska N, Buratti E, Baralle F, Villmann C *et al.* (2012). A retroelement modifies pre-mRNA splicing: the murine *Glrbspa* allele is a splicing signal polymorphism amplified by long interspersed nuclear element insertion. *J Biol Chem* 287: 31185–31194.
- Becker L, von Wegerer J, Schenkel J, Zeilhofer HU, Swandulla D, Weiher H (2002). Disease-specific human glycine receptor alpha1 subunit causes hyperekplexia phenotype and impaired glycine- and GABA(A)-receptor transmission in transgenic mice. *J Neurosci* 22: 2505–2512.
- Beckstead MJ, Phelan R, Trudell JR, Bianchini MJ, Mihic SJ (2002). Anesthetic and ethanol effects on spontaneously opening glycine receptor channels. *J Neurochem* 82: 1343–1351.
- Bellini G, Miceli F, Mangano S, Miraglia del Giudice E, Coppola G, Barbagallo A *et al.* (2007). Hyperekplexia caused by dominant-negative suppression of glyra1 function. *Neurology* 68: 1947–1949.
- Blednov YA, Benavidez JM, Homanics GE, Harris RA (2012). Behavioral characterization of knockin mice with mutations M287L and Q266I in the glycine receptor alpha1 subunit. *J Pharmacol Exp Ther* 340: 317–329.
- Bocquet N, Nury H, Baaden M, Le Poupon C, Changeux JP, Delarue M *et al.* (2009). X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation. *Nature* 457: 111–114.
- Borghese CM, Blednov YA, Quan Y, Iyer SV, Xiong W, Mihic SJ *et al.* (2012). Characterization of two mutations, M287L and Q266I, in the alpha1 glycine receptor subunit that modify sensitivity to alcohols. *J Pharmacol Exp Ther* 340: 304–316.
- Bork P, Holm L, Sander C (1994). The immunoglobulin fold. Structural classification, sequence patterns and common core. *J Mol Biol* 242: 309–320.
- Brams M, Gay EA, Saez JC, Guskov A, van Elk R, van der Schors RC *et al.* (2011a). Crystal structures of a cysteine-modified mutant in loop D of acetylcholine-binding protein. *J Biol Chem* 286: 4420–4428.
- Brams M, Pandya A, Kuzmin D, van Elk R, Krijnen L, Yakel JL *et al.* (2011b). A structural and mutagenic blueprint for molecular recognition of strychnine and d-tubocurarine by different cys-loop receptors. *PLoS Biol* 9: e1001034.
- Breiting HG, Becker CM (1998). The inhibitory glycine receptor: prospects for a therapeutic orphan. *Curr Pharm Des* 4: 315–334.

- Breitinger HG, Villmann C, Becker K, Becker CM (2001). Opposing effects of molecular volume and charge at the hyperekplexia site alpha 1(P250) govern glycine receptor activation and desensitization. *J Biol Chem* 276: 29657–29663.
- Breitinger HG, Villmann C, Melzer N, Rennert J, Breitinger U, Schwarzinger S *et al.* (2009). Novel regulatory site within the TM3-4 loop of human recombinant alpha3 glycine receptors determines channel gating and domain structure. *J Biol Chem* 284: 28624–28633.
- Brejic K, van Dijk WJ, Klaassen RV, Schuurmans M, Van Der Oost J, Smit AB *et al.* (2001). Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors. *Nature* 411: 269–276.
- Brune W, Weber RG, Saul B, von Knebel Doeberitz M, Grond-Ginsbach C, Kellerman K *et al.* (1996). A GLRA1 null mutation in recessive hyperekplexia challenges the functional role of glycine receptors. *Am J Hum Genet* 58: 989–997.
- Buchner DA, Trudeau M, Meisler MH (2003). SCN1M1, a putative RNA splicing factor that modifies disease severity in mice. *Science* 301: 967–969.
- Buckwalter MS, Cook SA, Davisson MT, White WF, Camper SA (1994). A frameshift mutation in the mouse alpha 1 glycine receptor gene (Gla1) results in progressive neurological symptoms and juvenile death. *Hum Mol Genet* 3: 2025–2030.
- Castaldo P, Stefanoni P, Miceli F, Coppola G, Del Giudice EM, Bellini G *et al.* (2004). A novel hyperekplexia-causing mutation in the pre-transmembrane segment 1 of the human glycine receptor alpha1 subunit reduces membrane expression and impairs gating by agonists. 279: 25598–25604.
- Cheng MH, Coalson RD, Cascio M (2008). Molecular dynamics simulations of ethanol binding to the transmembrane domain of the glycine receptor: implications for the channel potentiation mechanism. *Proteins* 71: 972–981.
- Chung SK, Vanbellinghen JF, Mullins JG, Robinson A, Hantke J, Hammond CL *et al.* (2010). Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia. *J Neurosci* 30: 9612–9620.
- Chung SK, Bode A, Cushion TD, Thomas RH, Hunt C, Wood SE *et al.* (2013). GLRB is the third major gene of effect in hyperekplexia. *Hum Mol Genet* 22: 927–940.
- Corringer PJ, Le Novère N, Changeux JP (2000). Nicotinic receptors at the amino acid level. *Annu Rev Pharmacol Toxicol* 40: 431–458.
- Coto E, Armenta D, Espinosa R, Argente J, Castro MG, Alvarez V (2005). Recessive hyperekplexia due to a new mutation (R100H) in the GLRA1 gene. *Mov Disord* 20: 1626–1629.
- Duret G, Van Renterghem C, Weng Y, Prevost M, Moraga-Cid G, Huon C *et al.* (2011). Functional prokaryotic-eukaryotic chimera from the pentameric ligand-gated ion channel family. *Proc Natl Acad Sci U S A* 108: 12143–12148.
- Duricic N, Godin AG, Wever CM, Heyes CD, Lakadamyali M, Dent JA (2012). Stoichiometry of the human glycine receptor revealed by direct subunit counting. *J Neurosci* 32: 12915–12920.
- Eichler SA, Forstera B, Smolinsky B, Juttner R, Lehmann TN, Fahling M *et al.* (2009). Splice-specific roles of glycine receptor alpha3 in the hippocampus. *Eur J Neurosci* 30: 1077–1091.
- Elmslie FV, Hutchings SM, Spencer V, Curtis A, Covanis T, Gardiner RM *et al.* (1996). Analysis of GLRA1 in hereditary and sporadic hyperekplexia: a novel mutation in a family cosegregating for hyperekplexia and spastic paraparesis. *J Med Genet* 33: 435–436.
- Filatov GN, White MM (1995). The role of conserved leucines in the M2 domain of the acetylcholine receptor in channel gating. *Mol Pharmacol* 48: 379–384.
- Findlay GS, Wick MJ, Mascia MP, Wallace D, Miller GW, Harris RA *et al.* (2002). Transgenic expression of a mutant glycine receptor decreases alcohol sensitivity of mice. *J Pharmacol Exp Ther* 300: 526–534.
- Findlay GS, Phelan R, Roberts MT, Homanics GE, Bergeson SE, Lopreato GF *et al.* (2003). Glycine receptor knock-in mice and hyperekplexia-like phenotypes: comparisons with the null mutant. *J Neurosci* 23: 8051–8059.
- Findlay GS, Harris RA, Blednov YA (2005). Male transgenic glycine receptor alpha1 (S267Q) mutant mice display a hyperekplexia-like increase in acoustic startle responses. *Pharmacol Biochem Behav* 82: 215–222.
- Forsyth RJ, Gika AD, Ginjaar I, Tijssen MA (2007). A novel GLRA1 mutation in a recessive hyperekplexia pedigree. *Mov Disord* 22: 1643–1645.
- Del Giudice EM, Coppola G, Bellini G, Cirillo G, Scuccimarra G, Pascotto A (2001). A mutation (V260M) in the middle of the M2 pore-lining domain of the glycine receptor causes hereditary hyperekplexia. *Eur J Hum Genet* 9: 873–876.
- Gilbert SL, Ozdag F, Ulas UH, Dobyns WB, Lahn BT (2004). Hereditary hyperekplexia caused by novel mutations of GLRA1 in Turkish families. *Mol Diagn* 8: 151–155.
- Graham BA, Schofield PR, Sah P, Margrie TW, Callister RJ (2006). Distinct physiological mechanisms underlie altered glycinergic synaptic transmission in the murine mutants spastic, spasmodic, and oscillator. *J Neurosci* 26: 4880–4890.
- Graham BA, Tadros MA, Schofield PR, Callister RJ (2011). Probing glycine receptor stoichiometry in superficial dorsal horn neurones using the spasmodic mouse. *J Physiol* 589 (Pt 10): 2459–2474.
- Grenningloh G, Schmieden V, Schofield PR, Seeburg PH, Siddique T, Mohandas TK *et al.* (1990). Alpha subunit variants of the human glycine receptor: primary structures, functional expression and chromosomal localization of the corresponding genes. *EMBO J* 9: 771–776.
- Grudzinska J, Schemm R, Haeger S, Nicke A, Schmalzing G, Betz H *et al.* (2005). The beta subunit determines the ligand binding properties of synaptic glycine receptors. *Neuron* 45: 727–739.
- Hansen SB, Sulzenbacher G, Huxford T, Marchot P, Taylor P, Bourne Y (2005). Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. *EMBO J* 24: 3635–3646.
- Harvey RJ, Topf M, Harvey K, Rees MI (2008). The genetics of hyperekplexia: more than startle! *Trends Genet* 24: 439–447.
- Hawthorne R, Lynch JW (2005). A picrotoxin-specific conformational change in the glycine receptor M2-M3 loop. *J Biol Chem* 280: 35836–35843.
- Hayashi T, Tachibana H, Kajii T (1991). Hyperekplexia: pedigree studies in two families. *Am J Med Genet* 40: 138–143.
- Hejazi N, Zhou C, Oz M, Sun H, Ye JH, Zhang L (2006). Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. *Mol Pharmacol* 69: 991–997.
- Hibbs RE, Gouaux E (2011). Principles of activation and permeation in an anion-selective Cys-loop receptor. *Nature* 474: 54–60.
- Hilf RJ, Dutzler R (2008). X-ray structure of a prokaryotic pentameric ligand-gated ion channel. *Nature* 452: 375–379.

- Hilf RJ, Dutzler R (2009). A prokaryotic perspective on pentameric ligand-gated ion channel structure. *Curr Opin Struct Biol* 19: 418–424.
- Hirzel K, Muller U, Latal AT, Hulsman S, Grudzinska J, Seeliger MW *et al.* (2006). Hyperekplexia phenotype of glycine receptor alpha1 subunit mutant mice identifies Zn(2+) as an essential endogenous modulator of glycinergic neurotransmission. *Neuron* 52: 679–690.
- Hoffmann J, Villmann C, Werner M, Hollmann M (2006). Investigation via ion pore transplantation of the putative relationship between glutamate receptors and K(+) channels. *Mol Cell Neurosci* 33: 358–370.
- Holland KD, Fleming MT, Cheek S, Moran JL, Beier DR, Meisler MH (2006). De novo exon duplication in a new allele of mouse Glra1 (spasmodic). *Genetics* 174: 2245–2247.
- Howard RJ, Murail S, Ondricek KE, Corringer PJ, Lindahl E, Trudell JR *et al.* (2011). Structural basis for alcohol modulation of a pentameric ligand-gated ion channel. *Proc Natl Acad Sci U S A* 108: 12149–12154.
- Hucho F, Weise C (2001). Ligand-gated ion channels. *Angew Chem Int Edit* 40: 3101–3116.
- Humeny A, Bonk T, Becker K, Jafari-Boroujerdi M, Stephani U, Reuter K *et al.* (2002). A novel recessive hyperekplexia allele GLRA1 (S231R): genotyping by MALDI-TOF mass spectrometry and functional characterisation as a determinant of cellular glycine receptor trafficking. *Eur J Hum Genet* 10: 188–196.
- James VM, Bode A, Chung SK, Gill JL, Nielsen M, Cowan FM *et al.* (2013). Novel missense mutations in the glycine receptor beta subunit gene (GLRB) in startle disease. *Neurobiol Dis* 52: 137–149.
- Jonas P, Bischofberger J, Sandkuhler J (1998). Corelease of two fast neurotransmitters at a central synapse. *Science* 281: 419–424.
- Karlin A, Akabas MH (1995). Toward a structural basis for the function of nicotinic acetylcholine receptors and their cousins. *Neuron* 15: 1231–1244.
- Keramidas A, Moorhouse AJ, Schofield PR, Barry PH (2004). Ligand-gated ion channels: mechanisms underlying ion selectivity. *Prog Biophys Mol Biol* 86: 161–204.
- Kingsmore SF, Giros B, Suh D, Bieniarz M, Caron MG, Seldin MF (1994). Glycine receptor beta-subunit gene mutation in spastic mouse associated with LINE-1 element insertion. *Nat Genet* 7: 136–141.
- Kirstein L, Silfverskiold BP (1958). A family with emotionally precipitated drop seizures. *Acta Psychiatr Neurol Scand* 33: 471–476.
- Kling C, Koch M, Saul B, Becker CM (1997). The frameshift mutation oscillator (Gla1(spdt)) produces a complete loss of glycine receptor alpha1-polypeptide in mouse central nervous system. *Neuroscience* 78: 411–417.
- Kotak VC, Korada S, Schwartz IR, Sanes DH (1998). A developmental shift from GABAergic to glycinergic transmission in the central auditory system. *J Neurosci* 18: 4646–4655.
- Kurczynski TW (1983). Hyperekplexia. *Arch Neurol* 40: 246–248.
- Kwok JB, Raskin S, Morgan G, Antoniuk SA, Bruk I, Schofield PR (2001). Mutations in the glycine receptor alpha1 subunit (GLRA1) gene in hereditary hyperekplexia pedigrees: evidence for non-penetrance of mutation Y279C. *J Med Genet* 38: E17.
- Langosch D, Laube B, Rundstrom N, Schmieden V, Bormann J, Betz H (1994). Decreased agonist affinity and chloride conductance of mutant glycine receptors associated with human hereditary hyperekplexia. *EMBO J* 13: 4223–4228.
- Lape R, Plested AJ, Moroni M, Colquhoun D, Sivilotti LG (2012). The alpha1K276E startle disease mutation reveals multiple intermediate states in the gating of glycine receptors. *J Neurosci* 32: 1336–1352.
- Lapunzina P, Sanchez JM, Cabrera M, Moreno A, Delicado A, de Torres ML *et al.* (2003). Hyperekplexia (startle disease): a novel mutation (S270T) in the M2 domain of the GLRA1 gene and a molecular review of the disorder. *Mol Diagn* 7: 125–128.
- Laube B, Kuhse J, Rundstrom N, Kirsch J, Schmieden V, Betz H (1995a). Modulation by zinc ions of native rat and recombinant human inhibitory glycine receptors. *J Physiol* 483 (Pt 3): 613–619.
- Laube B, Langosch D, Betz H, Schmieden V (1995b). Hyperekplexia mutations of the glycine receptor unmask the inhibitory subsite for beta-amino-acids. *Neuroreport* 6: 897–900.
- Laube B, Kuhse J, Betz H (2000). Kinetic and mutational analysis of Zn²⁺ modulation of recombinant human inhibitory glycine receptors. *J Physiol* 522 (Pt 2): 215–230.
- Laube B, Maksay G, Schemm R, Betz H (2002). Modulation of glycine receptor function: a novel approach for therapeutic intervention at inhibitory synapses? *Trends Pharmacol Sci* 23: 519–527.
- Lee CG, Kwon MJ, Yu HJ, Nam SH, Lee J, Ki CS *et al.* (2013). Clinical features and genetic analysis of children with hyperekplexia in Korea. *J Child Neurol* 28: 90–94.
- Lee WY, Free CR, Sine SM (2009). Binding to gating transduction in nicotinic receptors: Cys-loop energetically couples to pre-M1 and M2-M3 regions. *J Neurosci* 29: 3189–3199.
- Lewis TM, Sivilotti LG, Colquhoun D, Gardiner RM, Schoepfer R, Rees M (1998). Properties of human glycine receptors containing the hyperekplexia mutation alpha1(K276E), expressed in *Xenopus* oocytes. *J Physiol* 507 (Pt 1): 25–40.
- Li GD, Chiara DC, Sawyer GW, Husain SS, Olsen RW, Cohen JB (2006). Identification of a GABAA receptor anesthetic binding site at subunit interfaces by photolabeling with an etomidate analog. *J Neurosci* 26: 11599–11605.
- Lobo IA, Harris RA, Trudell JR (2008). Cross-linking of sites involved with alcohol action between transmembrane segments 1 and 3 of the glycine receptor following activation. *J Neurochem* 104: 1649–1662.
- Lynch JW (2004). Molecular structure and function of the glycine receptor chloride channel. *Physiol Rev* 84: 1051–1095.
- Lynch JW, Rajendra S, Barry PH, Schofield PR (1995). Mutations affecting the glycine receptor agonist transduction mechanism convert the competitive antagonist, picrotoxin, into an allosteric potentiator. *J Biol Chem* 270: 13799–13806.
- Lynch JW, Rajendra S, Pierce KD, Handford CA, Barry PH, Schofield PR (1997). Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel. *EMBO J* 16: 110–120.
- Lynch JW, Jacques P, Pierce KD, Schofield PR (1998). Zinc potentiation of the glycine receptor chloride channel is mediated by allosteric pathways. *J Neurochem* 71: 2159–2168.
- McCracken LM, Blednov YA, Trudell JR, Benavidez JM, Betz H, Harris RA (2013). Mutation of a zinc-binding residue in the glycine receptor alpha1 subunit changes ethanol sensitivity in vitro and alcohol consumption in vivo. *J Pharmacol Exp Ther* 344: 489–500.

- Machado P, Rostaing P, Guigonis JM, Renner M, Dumoulin A, Samson M *et al.* (2011). Heat shock cognate protein 70 regulates gephyrin clustering. *J Neurosci* 31: 3–14.
- McSwigan JD, Crabbe JC, Young ER (1984). Specific ethanol withdrawal seizures in genetically selected mice. *Life Sci* 35: 2119–2126.
- Malosio ML, Grenningloh G, Kuhse J, Schmieden V, Schmitt B, Prior P *et al.* (1991). Alternative splicing generates two variants of the alpha 1 subunit of the inhibitory glycine receptor. *J Biol Chem* 266: 2048–2053.
- Mascia MP, Machu TK, Harris RA (1996). Enhancement of homomeric glycine receptor function by long-chain alcohols and anaesthetics. *Br J Pharmacol* 119: 1331–1336.
- Melzer N, Villmann C, Becker K, Harvey K, Harvey RJ, Vogel N *et al.* (2010). Multifunctional basic motif in the glycine receptor intracellular domain induces subunit-specific sorting. *J Biol Chem* 285: 3730–3739.
- Mihic SJ, Ye Q, Wick MJ, Koltchine VV, Krasowski MD, Finn SE *et al.* (1997). Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. *Nature* 389: 385–389.
- Milani N, Dalpra L, Del Prete A, Zanini R, Larizza L (1996). A novel mutation (Gln266-->His) in the alpha 1 subunit of the inhibitory glycine-receptor gene (GLRA1) in hereditary hyperekplexia. *Am J Hum Genet* 58: 420–422.
- Miller PS, Smart TG (2010). Binding, activation and modulation of Cys-loop receptors. *Trends Pharmacol Sci* 31: 161–174.
- Miller PS, Topf M, Smart TG (2008). Mapping a molecular link between allosteric inhibition and activation of the glycine receptor. *Nat Struct Mol Biol* 15: 1084–1093.
- Miyazawa A, Fujiyoshi Y, Unwin N (2003). Structure and gating mechanism of the acetylcholine receptor pore. *Nature* 423: 949–955.
- Moorhouse AJ, Jacques P, Barry PH, Schofield PR (1999). The startle disease mutation Q266H, in the second transmembrane domain of the human glycine receptor, impairs channel gating. *Mol Pharmacol* 55: 386–395.
- Morley DJ, Weaver DD, Garg BP, Markand O (1982). Hyperplexia: an inherited disorder of the startle response. *Clin Genet* 21: 388–396.
- Mulhardt C, Fischer M, Gass P, Simon-Chazottes D, Guenet JL, Kuhse J *et al.* (1994). The spastic mouse: aberrant splicing of glycine receptor beta subunit mRNA caused by intronic insertion of L1 element. *Neuron* 13: 1003–1015.
- Muller E, Le Corrionc H, Triller A, Legendre P (2006). Developmental dissociation of presynaptic inhibitory neurotransmitter and postsynaptic receptor clustering in the hypoglossal nucleus. *Mol Cell Neurosci* 32: 254–273.
- Nikolic Z, Laube B, Weber RG, Lichter P, Kioschis P, Poustka A *et al.* (1998). The human glycine receptor subunit alpha3. Glra3 gene structure, chromosomal localization, and functional characterization of alternative transcripts. *J Biol Chem* 273: 19708–19714.
- Notelaers K, Smisdom N, Rocha S, Janssen D, Meier JC, Rigo JM *et al.* (2012). Ensemble and single particle fluorimetric techniques in concerted action to study the diffusion and aggregation of the glycine receptor alpha3 isoforms in the cell plasma membrane. *Biochim Biophys Acta* 1818: 3131–3140.
- Nury H, Bocquet N, Le Poupon C, Raynal B, Haouz A, Corringer PJ *et al.* (2010). Crystal structure of the extracellular domain of a bacterial ligand-gated ion channel. *J Mol Biol* 395: 1114–1127.
- O'Shea SM, Becker L, Weiher H, Betz H, Laube B (2004). Propofol restores the function of 'hyperekplexic' mutant glycine receptors in *Xenopus* oocytes and mice. *J Neurosci* 24: 2322–2327.
- Owen AG, Sherrington CS (1911). Observations on strychnine reversal. *J Physiol* 43: 232–241.
- Pfeiffer F, Graham D, Betz H (1982). Purification by affinity chromatography of the glycine receptor of rat spinal cord. *J Biol Chem* 257: 9389–9393.
- Pless SA, Lynch JW (2009). Magnitude of a conformational change in the glycine receptor beta1-beta2 loop is correlated with agonist efficacy. *J Biol Chem* 284: 27370–27376.
- Pless SA, Dibas MI, Lester HA, Lynch JW (2007). Conformational variability of the glycine receptor M2 domain in response to activation by different agonists. *J Biol Chem* 282: 36057–36067.
- Pless SA, Millen KS, Hanek AP, Lynch JW, Lester HA, Lummis SC *et al.* (2008). A cation-pi interaction in the binding site of the glycine receptor is mediated by a phenylalanine residue. *J Neurosci* 28: 10937–10942.
- Pribilla I, Takagi T, Langosch D, Bormann J, Betz H (1992). The atypical M2 segment of the beta subunit confers picrotoxinin resistance to inhibitory glycine receptor channels. *EMBO J* 11: 4305–4311.
- Rajendra S, Lynch JW, Pierce KD, French CR, Barry PH, Schofield PR (1994). Startle disease mutations reduce the agonist sensitivity of the human inhibitory glycine receptor. *J Biol Chem* 269: 18739–18742.
- Rajendra S, Lynch JW, Pierce KD, French CR, Barry PH, Schofield PR (1995). Mutation of an arginine residue in the human glycine receptor transforms beta-alanine and taurine from agonists into competitive antagonists. *Neuron* 14: 169–175.
- Rampon C, Luppi PH, Fort P, Peyron C, Jouvet M (1996). Distribution of glycine-immunoreactive cell bodies and fibers in the rat brain. *Neuroscience* 75: 737–755.
- Rea R, Tijssen MA, Herd C, Frants RR, Kullmann DM (2002). Functional characterization of compound heterozygosity for GlyRalpha1 mutations in the startle disease hyperekplexia. *Eur J Neurosci* 16: 186–196.
- Rees MI, Andrew M, Jawad S, Owen MJ (1994). Evidence for recessive as well as dominant forms of startle disease (hyperekplexia) caused by mutations in the alpha 1 subunit of the inhibitory glycine receptor. *Hum Mol Genet* 3: 2175–2179.
- Rees MI, Lewis TM, Vafa B, Ferrie C, Corry P, Muntoni F *et al.* (2001). Compound heterozygosity and nonsense mutations in the alpha(1)-subunit of the inhibitory glycine receptor in hyperekplexia. *Hum Genet* 109: 267–270.
- Rees MI, Lewis TM, Kwok JB, Mortier GR, Govaert P, Snell RG *et al.* (2002). Hyperekplexia associated with compound heterozygote mutations in the beta-subunit of the human inhibitory glycine receptor (GLRB). *Hum Mol Genet* 11: 853–860.
- Rundstrom N, Schmieden V, Betz H, Bormann J, Langosch D (1994). Cyanotriphenylborate: subtype-specific blocker of glycine receptor chloride channels. *Proc Natl Acad Sci U S A* 91: 8950–8954.
- Ryan SG, Dixon MJ, Nigro MA, Kelts KA, Markand ON, Terry JC *et al.* (1992a). Genetic and radiation hybrid mapping of the hyperekplexia region on chromosome 5q. *Am J Hum Genet* 51: 1334–1343.
- Ryan SG, Sherman SL, Terry JC, Sparkes RS, Torres MC, Mackey RW (1992b). Startle disease, or hyperekplexia: response to clonazepam

and assignment of the gene (STHE) to chromosome 5q by linkage analysis. *Ann Neurol* 31: 663–668.

Ryan SG, Buckwalter MS, Lynch JW, Handford CA, Segura L, Shiang R *et al.* (1994). A missense mutation in the gene encoding the alpha 1 subunit of the inhibitory glycine receptor in the spasmodic mouse. *Nat Genet* 7: 131–135.

Sadtler S, Laube B, Lashub A, Nicke A, Betz H, Schmalzing G (2003). A basic cluster determines topology of the cytoplasmic M3-M4 loop of the glycine receptor alpha1 subunit. *J Biol Chem* 278: 16782–16790.

Saitoh T, Ishida M, Maruyama M, Shinozaki H (1994). A novel antagonist, phenylbenzene omega-phosphono-alpha-amino acid, for strychnine-sensitive glycine receptors in the rat spinal cord. *Br J Pharmacol* 113: 165–170.

Sauguet L, Howard RJ, Malherbe L, Lee US, Corringer PJ, Harris RA *et al.* (2013). Structural basis for potentiation by alcohols and anaesthetics in a ligand-gated ion channel. *Nature Commun* 4: 1697.

Saul B, Schmieden V, Kling C, Mulhardt C, Gass P, Kuhse J *et al.* (1994). Point mutation of glycine receptor alpha 1 subunit in the spasmodic mouse affects agonist responses. *FEBS Lett* 350: 71–76.

Saul B, Kuner T, Sobetzko D, Brune W, Hanefeld F, Meinck HM *et al.* (1999). Novel GLRA1 missense mutation (P250T) in dominant hyperekplexia defines an intracellular determinant of glycine receptor channel gating. *J Neurosci* 19: 869–877.

Schaefer N, Vogel N, Villmann C (2012). Glycine receptor mutants of the mouse: what are possible routes of inhibitory compensation. *Front Mol Neurosci* 5: 98.

Schmieden V, Betz H (1995). Pharmacology of the inhibitory glycine receptor: agonist and antagonist actions of amino acids and piperidine carboxylic acid compounds. *Mol Pharmacol* 48: 919–927.

Schoneberg T, Liu J, Wess J (1995). Plasma membrane localization and functional rescue of truncated forms of a G protein-coupled receptor. *J Biol Chem* 270: 18000–18006.

Schoneberg T, Yun J, Wenkert D, Wess J (1996). Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. *EMBO J* 15: 1283–1291.

Seri M, Bolino A, Galletta LJ, Lerone M, Silengo M, Romeo G (1997). Startle disease in an Italian family by mutation (K276E): the alpha-subunit of the inhibiting glycine receptor. *Hum Mutat* 9: 185–187.

Shan Q, Lynch JW (2012). Incompatibility between a pair of residues from the pre-M1 linker and Cys-loop blocks surface expression of the glycine receptor. *J Biol Chem* 287: 7535–7542.

Shan Q, Haddrill JL, Lynch JW (2001a). Ivermectin, an unconventional agonist of the glycine receptor chloride channel. *J Biol Chem* 276: 12556–12564.

Shan Q, Haddrill JL, Lynch JW (2001b). A single beta subunit M2 domain residue controls the picrotoxin sensitivity of alphabeta heteromeric glycine receptor chloride channels. *J Neurochem* 76: 1109–1120.

Shiang R, Ryan SG, Zhu YZ, Hahn AF, O'Connell P, Wasmuth JJ (1993). Mutations in the alpha 1 subunit of the inhibitory glycine receptor cause the dominant neurologic disorder, hyperekplexia. *Nat Genet* 5: 351–358.

Shiang R, Ryan SG, Zhu YZ, Fielder TJ, Allen RJ, Fryer A *et al.* (1995). Mutational analysis of familial and sporadic hyperekplexia. *Ann Neurol* 38: 85–91.

Suhren O, Bruyn GW, Tyuynman JA (1966). Hyperekplexia – a hereditary startle syndrome. *J Neurol Sci* 3: 577–605.

Sunesen M, de Carvalho LP, Dufresne V, Grailhe R, Savatier-Duclert N, Gibor G *et al.* (2006). Mechanism of Cl⁻ selection by a glutamate-gated chloride (GluCl) receptor revealed through mutations in the selectivity filter. *J Biol Chem* 281: 14875–14881.

Tang P, Mandal PK, Xu Y (2002). NMR structures of the second transmembrane domain of the human glycine receptor alpha(1) subunit: model of pore architecture and channel gating. *Biophys J* 83: 252–262.

Thompson AJ, Lester HA, Lummis SC (2010). The structural basis of function in Cys-loop receptors. *Q Rev Biophys* 43: 449–499.

Todorovic J, Welsh BT, Bertaccini EJ, Trudell JR, Mihic SJ (2010). Disruption of an intersubunit electrostatic bond is a critical step in glycine receptor activation. *Proc Natl Acad Sci U S A* 107: 7987–7992.

Traka M, Seburn KL, Popko B (2006). Nmf11 is a novel ENU-induced mutation in the mouse glycine receptor alpha 1 subunit. *Mamm Genome* 17: 950–955.

Tsai CH, Chang FC, Su YC, Tsai FJ, Lu MK, Lee CC *et al.* (2004). Two novel mutations of the glycine receptor gene in a Taiwanese hyperekplexia family. *Neurology* 63: 893–896.

Unterer B, Becker CM, Villmann C (2012). The importance of TM3-4 loop subdomains for functional reconstitution of glycine receptors by independent domains. *J Biol Chem* 287: 39205–39215.

Unwin N (1995). Acetylcholine receptor channel imaged in the open state. *Nature* 373: 37–43.

Unwin N (2005). Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution. *J Mol Biol* 346: 967–989.

Valenzuela CF, Cardoso RA, Wick MJ, Weiner JL, Dunwiddie TV, Harris RA (1998). Effects of ethanol on recombinant glycine receptors expressed in mammalian cell lines. *Alcohol Clin Exp Res* 22: 1132–1136.

Valkova C, Albrizio M, Roder IV, Schwake M, Betto R, Rudolf R *et al.* (2011). Sorting receptor Rer1 controls surface expression of muscle acetylcholine receptors by ER retention of unassembled alpha-subunits. *Proc Natl Acad Sci U S A* 108: 621–625.

Vallee BL (1998). Alcohol in the western world. *Sci Am* 278: 80–85.

Vergouwe MN, Tijssen MA, Peters AC, Wielaard R, Frants RR (1999). Hyperekplexia phenotype due to compound heterozygosity for GLRA1 gene mutations. *Ann Neurol* 46: 634–638.

Villmann C, Oertel J, Ma-Hogemeier ZL, Hollmann M, Sprengel R, Becker K *et al.* (2009a). Functional complementation of Glra1(spdt-ot), a glycine receptor subunit mutant, by independently expressed C-terminal domains. *J Neurosci* 29: 2440–2452.

Villmann C, Oertel J, Melzer N, Becker CM (2009b). Recessive hyperekplexia mutations of the glycine receptor alpha1 subunit affect cell surface integration and stability. *J Neurochem* 111: 837–847.

Vogel N, Kluck CJ, Melzer N, Schwarzingen S, Breiteringer U, Seeber S *et al.* (2009). Mapping of disulfide bonds within the amino-terminal extracellular domain of the inhibitory glycine receptor. *J Biol Chem* 284: 36128–36136.

Wang DS, Mangin JM, Moonen G, Rigo JM, Legendre P (2006). Mechanisms for picrotoxin block of alpha2 homomeric glycine receptors. *J Biol Chem* 281: 3841–3855.

Wang L, Li WG, Huang C, Zhu MX, Xu TL, Wu DZ *et al.* (2012). Subunit-specific inhibition of glycine receptors by curcuminol. *J Pharmacol Exp Ther* 343: 371–379.

- Xiong W, Cheng K, Cui T, Godlewski G, Rice KC, Xu Y *et al.* (2011). Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. *Nat Chem Biol* 7: 296–303.
- Xiong W, Cui T, Cheng K, Yang F, Chen SR, Willenbring D *et al.* (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycinereceptors. *J Exp Med* 209: 1121–1134.
- Xu M, Akabas MH (1996). Identification of channel-lining residues in the M2 membrane-spanning segment of the GABA(A) receptor alpha1 subunit. *J Gen Physiol* 107: 195–205.
- Yang Z, Taran E, Webb TI, Lynch JW (2012). Stoichiometry and subunit arrangement of alpha1beta glycine receptors as determined by atomic force microscopy. *Biochemistry* 51: 5229–5231.
- Yevenes GE, Zeilhofer HU (2011a). Allosteric modulation of glycine receptors. *Br J Pharmacol* 164: 224–236.
- Yevenes GE, Zeilhofer HU (2011b). Molecular sites for the positive allosteric modulation of glycine receptors by endocannabinoids. *PLoS ONE* 6: e23886.
- Yevenes GE, Moraga-Cid G, Guzman L, Haeger S, Oliveira L, Olate J *et al.* (2006). Molecular Determinants for G Protein beta[gamma] Modulation of Ionotropic Glycine Receptors. *J Biol Chem* 281: 39300–39307.
- Zhang D, Pan ZH, Zhang X, Brideau AD, Lipton SA (1995). Cloning of a gamma-aminobutyric acid type C receptor subunit in rat retina with a methionine residue critical for picrotoxinin channel block. *Proc Natl Acad Sci U S A* 92: 11756–11760.
- Zhong W, Gallivan JP, Zhang Y, Li L, Lester HA, Dougherty DA (1998). From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor. *Proc Natl Acad Sci U S A* 95: 12088–12093.